Fenazoxine; 5-Methyl-1-phenyl-3,4,5,6-tetrahydro-1H-benzo[f][1,4]oxazocine; Nefopamum; 5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine; Sinalgico; 5-Methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine; Nefopam [INN:BAN]; Nefopamum [INN-Latin]; EINECS 237-148-2; 1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl-; Nefopam (INN); Spectrum_001376; 3,4,5,6-Tetrahydro-5-methyl-1-phenyl-1H-2,5-benzoxazocin; ACMC-20dgj4; Prestwick0_000229; Prestwick1_000229; Prestwick2_000229; Prestwick3_000229; Spectrum2_001416; Spectrum3_000912; Spectrum4_001011; Spectrum5_001349; Oprea1_350502; SCHEMBL23646; BSPBio_000277; KBioGR_001501; KBioSS_001856; DivK1c_000384; SPECTRUM1501137; SPBio_001492; SPBio_002198; BPBio1_000305; CHEMBL465026; 1H-2,5-Benzoxazocine,3,4,5,6-tetrahydro-5-methyl-1-phenyl-, (1S)-; DTXSID2048535; CTK8B4975; HMS501D06; KBio1_000384; KBio2_001856; KBio2_004424; KBio2_006992; KBio3_001884; NINDS_000384; 3,4,5,6-Tetrahydro-5-methyl-1-phenyl-1H-2,5-benzoxazocine; HMS1921J03; HMS2092F11; Pharmakon1600-01501137; ACT02693; ANW-46932; BDBM50237616; CCG-38969; NSC757856; STL483795; 1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- (8CI,9CI); AKOS001582723; AKOS016842440; ACN-053735; DB12293; MCULE-2635908358; NSC-757856; IDI1_000384; NCGC00094906-01; NCGC00094906-02; NCGC00094906-03; NCGC00094906-07; AC-12146; BR-58613; SBI-0051651.P002; DB-042351; AB00052213; FT-0630408; X9955; D08258; S-6281; AB00052213_09; AB00052213_10; 669N700; A807114; Q599052; J-006886; SR-01000388442-3; BRD-A78877355-003-03-6; 3,4,5,6-Tetrahydro-5-methyl-2-phenyl-1H-2,5-benzoxazocine; 5-Methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine #; 3-Methyl-7-phenyl-6-oxa-3-azabicyclo[6.4.0]dodeca-8,10,12-triene